VYTRUS BIOTECH EO -01 - Asset Resilience Ratio

Latest as of December 2025: 0.00%

VYTRUS BIOTECH EO -01 (V5P) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of VYTRUS BIOTECH EO -01 to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€600.00
≈ $701.46 USD Cash + Short-term Investments

Total Assets

€14.66 Million
≈ $17.14 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how VYTRUS BIOTECH EO -01's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see V5P total asset value.

Liquid Assets Composition Over Time

This chart breaks down VYTRUS BIOTECH EO -01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read VYTRUS BIOTECH EO -01 balance sheet liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €600.00 0.0%
Total Liquid Assets €600.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: VYTRUS BIOTECH EO -01 maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

VYTRUS BIOTECH EO -01 Industry Peers by Asset Resilience Ratio

Compare VYTRUS BIOTECH EO -01's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Biotechnology 16.06%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Revolution Medicines Inc
NASDAQ:RVMD
Biotechnology 72.23%
Abivax SA
PA:ABVX
Biotechnology 2.34%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
SOLENO THERAPEUT. DL-001
F:6XC
Biotechnology 41.74%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

Annual Asset Resilience Ratio for VYTRUS BIOTECH EO -01 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for VYTRUS BIOTECH EO -01.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.00% €600.00
≈ $701.46
€14.66 Million
≈ $17.14 Million
0.00pp
2024-12-31 0.01% €600.00
≈ $701.46
€11.13 Million
≈ $13.01 Million
0.00pp
2023-12-31 0.01% €600.00
≈ $701.46
€9.31 Million
≈ $10.89 Million
0.00pp
2021-12-31 0.01% €522.14
≈ $610.44
€7.18 Million
≈ $8.40 Million
--
pp = percentage points

About VYTRUS BIOTECH EO -01

F:V5P Germany Biotechnology
Market Cap
$143.68 Million
€122.89 Million EUR
Market Cap Rank
#18343 Global
#1704 in Germany
Share Price
€16.35
Change (1 day)
+0.00%
52-Week Range
€4.82 - €21.60
All Time High
€21.60
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more